Ad
related to: difference between ivig and scig technology solutions
Search results
Results From The WOW.Com Content Network
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [13] [14] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
Anti-tetanus immunoglobulin, also known as tetanus immune globulin (TIG) and tetanus antitoxin, is a medication made up of antibodies against the tetanus toxin. [1] It is used to prevent tetanus in those who have a wound that is at high risk, have not been fully vaccinated with tetanus toxoid, or have HIV/AIDS.
Anti-D is recommended as a first-line therapy for ITP, along with corticosteroids and intravenous immune globulin (IVIG). [20] [22] [WinRho SDF is an anti-D manufactured, distributed and marketed by Cangene in the US.
This page was last edited on 12 December 2019, at 17:55 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
From Wikipedia, the free encyclopedia. Redirect page
Intravenous immunoglobulin (IVIG) is treatment of choice. [36] [38] Transfusion-related acute lung injury (TRALI) is a syndrome that is similar to acute respiratory distress syndrome (ARDS), which develops during or within 6 hours of transfusion of a plasma-containing blood product. Fever, hypotension, shortness of breath, and tachycardia often ...
One of the key classifications is between traditional small molecule drugs; usually derived from chemical synthesis and biological medical products; which include recombinant proteins, vaccines, blood products used therapeutically (such as IVIG), gene therapy, and cell therapy (for instance, stem cell therapies). [citation needed]
The concept of blocking PD-1 and PD-L1 for the treatment of cancer was first published in 2001. [6] Pharmaceutical companies began attempting to develop drugs to block these molecules, and the first clinical trial was launched in 2006, evaluating nivolumab.